Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RTCA antisense RNA 1 (RTCA-AS1) is a human long non-coding antisense RNA, identified for its marked positive correlation with chromatin-modifying protein 4 (CHMP4A), a component of the ESCRT-III complex involved in endosomal sorting and autophagy-related pathways[5]. As a lncRNA, RTCA-AS1 likely regulates the expression and function of nearby or overlapping protein-coding genes by antisense mechanisms, including chromatin remodeling and mRNA stability modulation, roles broadly established for antisense lncRNAs in gene regulation[6]. RTCA-AS1 has been associated through gene expression analysis with cancer-related regulatory networks but is not a conventional receptor, enzyme, or druggable protein target[5].\n\nNo known therapeutics, biomarkers, or safety concerns have been documented for RTCA-AS1, and it is not considered an established therapeutic target at this time.
Not applicable; as RTCA-AS1 is not directly targeted by drugs, mechanisms relate to its natural gene regulatory function (e.g., antisense RNA regulatory effects, chromatin modification through interaction partners)[5][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RTCA antisense RNA 1 (RTCA-AS1).